Vaccination to prevent vaginal cancer due to human papillomavirus

Vaginal cancer due to human papillomavirus (HPV) is a rare malignant neoplasm of the female lower genital tract, predominantly presenting as squamous cell carcinoma within the vaginal mucosa The disease arises from persistent mucosal infection with oncogenic, high-risk HPV types—most commonly HPV-16 and HPV-18—whose viral oncoproteins disrupt cell cycle regulation and promote progressive dysplasia, advancing from high-grade vaginal intraepithelial neoplasia (VaIN 2/3) to invasive malignancy Vacc...

Vaginal cancer due to human papillomavirus (HPV) is a rare malignant neoplasm of the female lower genital tract, predominantly presenting as squamous cell carcinoma within the vaginal mucosa Vaccination against HPV is a prophylactic strategy indicated in eligible females to stimulate neutralizing antibodies against targeted viral capsids, thereby preventing initial high-risk HPV infection and interrupting the oncogenic cascade before precancerous or malignant transformation occurs

Vaginal cancer due to human papillomavirus (HPV) is a rare malignant neoplasm of the female lower genital tract, predominantly presenting as squamous cell carcinoma within the vaginal mucosa

The disease arises from persistent mucosal infection with oncogenic, high-risk HPV types—most commonly HPV-16 and HPV-18—whose viral oncoproteins disrupt cell cycle regulation and promote progressive dysplasia, advancing from high-grade vaginal intraepithelial neoplasia (VaIN 2/3) to invasive malignancy

The disease arises from persistent mucosal infection with oncogenic, high-risk HPV types—most commonly HPV-16 and HPV-18—whose viral oncoproteins disrupt cell cycle regulation and promote progressive dysplasia, advancing from high-grade vaginal intraepithelial neoplasia (VaIN 2/3) to invasive malignancy

Vaccination against HPV is a prophylactic strategy indicated in eligible females to stimulate neutralizing antibodies against targeted viral capsids, thereby preventing initial high-risk HPV infection and interrupting the oncogenic cascade before precancerous or malignant transformation occurs